AMN Healthcare (AMN) Q1 2026 earnings review
A $722 Million Strike Windfall Masks Underlying Headwinds
AMN Healthcare delivered a staggering optical beat in Q1 2026, with revenue doubling year-over-year to $1.38 billion and Adjusted EBITDA skyrocketing 159%. However, this was almost entirely driven by $722 million in temporary labor disruption (strike) revenue. Stripping this away reveals a core business that generated roughly $656 million in revenue—stabilizing quarter-over-quarter, but still facing significant structural pressures. Q2 2026 guidance shatters the illusion: revenue is projected to reverse violently back to $620-$635 million, and Adjusted EBITDA margins will decelerate from Q1's 12.1% down to a multi-year low of ~7.0%. While the strike windfall fortified the balance sheet by driving leverage down to 1.6x, the core reality is a company grappling with margin compression, intense pricing competition, and shrinking technology segment revenues.
🐂 Bull Case
Flawlessly executing a $722M strike response while growing core travel nursing volume YoY validates AMN's investments in its proprietary event management system and AI matching capabilities.
The massive cash influx allowed AMN to pay down its revolving credit facility to zero. Net leverage plummeted from 3.3x to 1.6x, providing immense strategic and capital allocation flexibility.
🐻 Bear Case
Q1 Adjusted EBITDA margins spiked to 12.1% purely on operating leverage from the strike. With Q2 guidance targeting ~7.0%, the structural erosion of AMN's core profitability becomes glaringly apparent.
The Technology and Workforce Solutions segment continues to be a major laggard, declining 15% YoY in Q1 with guidance for another 14-16% drop in Q2, driven by VMS runoff and intense Language Services pricing pressure.
⚖️ Verdict: 🔴
Bearish. Do not be fooled by the headline numbers. Q1 was a one-off anomaly. The underlying trajectory points to reversing revenues, collapsing margins, and a core market that has yet to demonstrate sustainable pricing power.
Key Themes
The Cash Flow Illusion
AMN reported a massive $562 million in Q1 Operating Cash Flow, which looks spectacular on paper. However, management explicitly noted that this balance benefited from favorable working capital timing, specifically $367 million in client deposits for labor disruption events that must be settled in the coming months. Underlying cash flow generation is significantly lower, and investors should expect a substantial working capital drag in Q2 as these deposits unwind.
Core Nursing Returns to Growth
Buried beneath the strike noise is a genuinely positive data point: Travel nursing volume and revenue grew year-over-year for the first time since 2022. The Nurse and Allied Solutions segment (excluding disruption) showed solid sequential momentum. This indicates that the aggressive post-pandemic destocking and rate normalization phase is finally stabilizing, laying a base for future core growth.
Technology & Workforce Solutions Bleeding Continues
TWS is decelerating further. Revenue fell 15% YoY to $87 million. Vendor Management Systems (VMS) plummeted 18% to $16 million, while Language Services—previously a growth engine—dropped 8% YoY to $69 million due to severe pricing pressure from an aggressive competitor consolidator. Q2 guidance calls for a 14-16% YoY decline. The segment that was supposed to drive high-margin diversification is actively shrinking.
Severe Underlying Margin Erosion
Gross margins are flashing warning signs. Despite the massive Q1 volume, consolidated gross margin fell 190 basis points YoY to 26.8%. More alarmingly, Q2 guidance projects Adjusted EBITDA margin to compress to 6.7-7.2%. This confirms that AMN's core business currently lacks the pricing power necessary to maintain historical profitability levels against ongoing wage inflation and competitive bidding.
AI & Event Management Tech Investment Pays Off
Management attributed their ability to seamlessly absorb $722 million in strike orders without disrupting the core business to their proprietary 'event management system' and AI-enhanced recruiter tools. This tech stack is a tangible moat; it provides a speed-to-fill advantage that competitors cannot easily replicate during sudden market shocks.
Other KPIs
Reversing. The Q1 surge to 12.1% (up 280 bps from Q4 2025's 9.3%) was purely transient operating leverage from the labor disruption events. The Q2 guidance represents a violent deceleration, dropping below the 2025 average of 8.6% and highlighting the margin-dilutive nature of the current core competitive environment.
Accelerating improvement. Leverage plunged from 3.1x at the end of Q1 2025 (and 3.3x at the end of Q4 2025) to just 1.6x. The company utilized Q1 cash flow to pay down its revolving credit facility to zero, ending the quarter with $750 million in total debt and $561 million in cash (though $367M is tied to temporary deposits). This fortress balance sheet removes existential risk and prepares AMN for potential M&A.
Guidance
Reversing. After an artificially inflated $1.378 billion in Q1, revenue will return to Earth. The midpoint represents a 4-6% decline YoY, though excluding the labor disruption impacts, core revenue is guided down 3-5% YoY. This indicates the core business is still shrinking, albeit at a slower pace than in early 2025.
Decelerating sharply. Down from 12.1% in Q1 and down from 8.9% in Q2 2025. Management expects SG&A as a percentage of revenue to climb to 23.0-23.5% (up from 15.8% in Q1) as the massive denominator effect of the strike revenue disappears, exposing a heavy fixed-cost base.
Stable. This is a massive improvement from the double-digit YoY declines seen throughout 2024 and early 2025. It indicates that the core nursing market has finally found its floor.
Decelerating. The segment declined 6% YoY in Q1, and guidance implies continued or slightly worsening pressure, largely driven by disruptions to the Locum Tenens business and general hospital cost containment.
Key Questions
Margin Floor Visibility
With Q2 Adjusted EBITDA margin guided to ~7%, how much of this compression is structural due to permanent bill rate/pay rate spread tightening versus temporary deleveraging? Where do you see the absolute floor for core margins?
Working Capital Reversal
Of the $561 million in quarter-end cash, $367 million represents client deposits. What is the precise timing of the expected cash outflows to settle these deposits in Q2 and Q3, and what is your normalized Free Cash Flow expectation for FY26?
TWS Segment Turnaround
The Technology and Workforce Solutions segment is guiding to a 14-16% decline. Given the stated pricing pressures in Language Services and VMS runoff, what is the strategic roadmap and timeline for returning this higher-margin segment to growth?
Capital Allocation Post-Deleveraging
With net leverage dropping to 1.6x and the revolver paid off, you have achieved significant balance sheet flexibility. How does this alter your capital allocation priorities between M&A, share repurchases, and further debt reduction?